IL6 and atherosclerosis: Three processes are crucial in the interface between CHIP and ASCVD: (1) CHIP upregulates the inflammasome/IL-1/IL-6 pathway; (2) CHIP increases ASCVD risk in a dose-dependent manner, with larger mutated leukocyte clones being associated with higher ASCVD risk; (3) atherosclerosis promotes CHIP progression.